SAN FRANCISCO, Jan. 11, 2016 /PRNewswire/ -- Bracket, a leading clinical trial specialty services provider, has released version 4.0 of Rater Stationâ , an innovative Electronic Clinical Outcomes Assessment (eCOA) tool designed to improve performance and outcomes in clinical trials. The Rater Stationâ platform has been used extensively in Central Nervous System clinical trials, and version 4.0 is currently being used in two clinical trials that are actively recruiting.
Precision at Every Step
Bracket's Rater Stationâ , an enhanced type of electronic Clinician-Reported Outcome (eClinRO), uniquely features intelligent design that provides added clinical value and quality control. Rater Stationâ has been used in dozens of pivotal worldwide studies, and is a core component of Bracket's eCOA platform.
"The Rater Stationâ intelligent question design improves data quality while reducing investigator and patient burden. This release incorporates the feedback of more than 20 stakeholders, and is our most usable and secure version yet," stated David G. Daniel, MD, Chief Medical Officer for Bracket.
In addition to a completely re-designed user interface, this release incorporates several critical improvements which enable sites to conduct their clinical interviews more accurately. These improvements include:
Persistent Auto-Save, loss of power, user error, or system malfunction will never mean lost data.
Advanced authentication and user management features, allowing study sponsors more granular control of which site personnel can access data.
A new and improved Question Library, allows for advanced customization for each scale and questionnaire programmed into the platform.
Improved clinical edit checks, designed to reduce errors and minimize burdensome data corrections.
New workflow that streamlines subject visits for study personnel.
"The reliable application of outcome measures is crucial to conducting high quality trials. Innovative technology can help with this issue. However, it is crucial that when introducing new technology, we take care to make patient assessment easier for site staff. Technologies such as Rater Stationâ can help improve trial conduct and, through intuitive design, aid patient assessment," stated John Harrison, PhD, Associate Professor Alzheimer Center at the VU University Medical Center, Amsterdam, and a member of Bracket's Scientific Advisory Board.
About Bracket
Bracket, with seven offices and more than 500 employees worldwide, is a specialty services provider dedicated to helping biopharmaceutical sponsors and contract research organizations increase the power of their clinical research data by leveraging core competencies in Science, Technology, and Service. Bracket eCOA™ is a flexible platform for electronic clinical outcomes assessments. Bracket RTSM™ is a best-in-breed, scalable and configurable clinical IRT solution for the life sciences industry. Bracket Rater Training and Quality Assurance improve outcomes through customized training and quality assurance programs.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.